Neuroprotective effects of 5-aminolevulinic acid against neurodegeneration in rat models of Parkinson's disease and stroke

J Pharmacol Sci. 2020 Nov;144(3):183-187. doi: 10.1016/j.jphs.2020.07.012. Epub 2020 Aug 1.

Abstract

Oxidative stress is associated with the progression of the neurodegenerative diseases Parkinson's disease (PD) and cerebral ischemia. Recently, 5-aminolevulinic acid (5-ALA), an intermediate in the porphyrin synthesis pathway, was reported to exert antioxidative effects on macrophages and cardiomyocytes. Here, we demonstrated the neuroprotective effects of 5-ALA using rat models of PD and ischemia as well as in vitro in SH-SY5Y cells. 5-ALA partially prevented neurodegeneration in each condition. These results suggest that 5-ALA has a potential for promising therapeutic agent to protect against neurodegeneration exacerbated by oxidative stress.

Keywords: 5-Aminolevulinic acid; Neuroprotection; Oxidative stress.

MeSH terms

  • Aminolevulinic Acid
  • Animals
  • Brain Ischemia / etiology
  • Brain Ischemia / pathology*
  • Cell Line, Tumor
  • Disease Models, Animal
  • Humans
  • Levulinic Acids / pharmacology*
  • Levulinic Acids / therapeutic use
  • Male
  • Nerve Degeneration* / prevention & control
  • Neuroprotective Agents*
  • Oxidative Stress / drug effects*
  • Parkinson Disease / etiology
  • Parkinson Disease / pathology*
  • Rats, Wistar
  • Stroke / etiology
  • Stroke / pathology*

Substances

  • Levulinic Acids
  • Neuroprotective Agents